Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab
Open Access
- 13 September 2024
- journal article
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (5) , 101100
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (32100745, 31971129, 82272301)
- Innovative Research Group Project of the National Natural Science Foundation of China
- National Key Research and Development Program of China (2022YFC2304102, 2022YFC2303300)
This publication has 51 references indexed in Scilit:
- Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinomaInternational Immunopharmacology, 2023
- Periostin deficiency reduces PD-1+ tumor-associated macrophage infiltration and enhances anti-PD-1 efficacy in colorectal cancerCell Reports, 2023
- Mirvetuximab Soravtansine: First ApprovalDrugs, 2023
- Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in OncologyClinical Pharmacokinetics, 2022
- The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesCell, 2022
- A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumorsMolecular Therapy, 2022
- DDR1 associates with TRPV4 in cell‐matrix adhesions to enable calcium‐regulated myosin activity and collagen compactionJournal of Cellular Physiology, 2022
- LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 studyAnnals of Oncology, 2021
- Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer PatientsAdvances in Therapy, 2019
- Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinomaMolecular Oncology, 2019